230 related articles for article (PubMed ID: 7591211)
21. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
24. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
[TBL] [Abstract][Full Text] [Related]
25. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
27. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.
Borchmann P; Treml JF; Hansen H; Gottstein C; Schnell R; Staak O; Zhang HF; Davis T; Keler T; Diehl V; Graziano RF; Engert A
Blood; 2003 Nov; 102(10):3737-42. PubMed ID: 12881320
[TBL] [Abstract][Full Text] [Related]
28. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Ghetie MA; Tucker K; Richardson J; Uhr JW; Vitetta ES
Blood; 1992 Nov; 80(9):2315-20. PubMed ID: 1384801
[TBL] [Abstract][Full Text] [Related]
29. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains.
Ghetie V; Engert A; Schnell R; Vitetta ES
Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
[TBL] [Abstract][Full Text] [Related]
31. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
33. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells.
Renner C; Jung W; Sahin U; Denfeld R; Pohl C; Trümper L; Hartmann F; Diehl V; van Lier R; Pfreundschuh M
Science; 1994 May; 264(5160):833-5. PubMed ID: 8171337
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin.
Hansen HP; Matthey B; Barth S; Kisseleva T; Mokros T; Davies SJ; Beckett RP; Foelster-Holst R; Lange HH; Engert A; Lemke H
Int J Cancer; 2002 Mar; 98(2):210-5. PubMed ID: 11857410
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells.
Heuser C; Diehl V; Abken H; Hombach A
Int J Cancer; 2003 Sep; 106(4):545-552. PubMed ID: 12845650
[TBL] [Abstract][Full Text] [Related]
36. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
37. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
38. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
39. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).
Matthey B; Engert A; Barth S
Int J Mol Med; 2000 Nov; 6(5):509-14. PubMed ID: 11029515
[TBL] [Abstract][Full Text] [Related]
40. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig MT; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann ML; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
Blood; 1997 Jan; 89(2):403-10. PubMed ID: 9002941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]